Liver Cancer

Published Date : Nov 2023
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Overview of the Global Liver Cancer Market

The threat of liver cancer, a powerful concern in the field of oncology, is becoming a growing cause of global stress. One of the most prevalent cancers worldwide is liver cancer. The World Cancer Research Fund predicted that 905,677 new instances of liver cancer will be diagnosed worldwide in 2020, making it the sixth most frequent cancer.

Hepatocellular carcinoma (HCC), another name for liver cancer, is a cancerous tumor that develops in the cells of the liver, usually as a result of chronic liver disease, viral hepatitis infections, or other risk factors. It is characterized by uncontrollable liver cell development, which harms the functioning of the liver and causes several health issues.

There are broadly two types of liver cancers - primary and secondary liver cancers.  Most of the primary liver cancers originate from the epithelial tissue of the liver and rarely from the non-epithelial tissue of the liver. The secondary cancers include various cancers that originate from other organs such as the pancreas, colon, stomach, breast, or lung and metastasize (spread) to the liver.

Hepatocellular carcinoma is the most common type of liver cancer, although intrahepatic cholangiocarcinoma, angiosarcoma, and hemangiosarcoma are less frequent types. Males over females are significantly more likely to develop hepatocellular cancer.

Hepatocellular carcinoma (HCC), the most common type of liver cancer in adults, often appears in those who have cirrhosis or chronic (long-lasting) liver disease brought on by hepatitis virus infection. Hepatocellular carcinoma represents approximately 90% of primary liver cancers, followed by intrahepatic cholangiocarcinoma and other primary liver malignancies.

Approximately 90% of hepatocellular carcinomas are associated with a known underlying cause, most commonly chronic viral hepatitis, heavy alcohol use, and non-alcoholic fatty liver disease. Other risk factors include obesity, diabetes, exposure to aflatoxins (toxins produced by molds), and genetic factors that have emerged as a significant global health issue.

As per NIH, HCC is more common in men than in women. Multiple risk factors increase a person's risk even further. In terms of prevalence, it ranks ninth among cancers in women and fifth among cancers in males.

Hepatitis C infection is the more frequent cause of HCC in the US, but hepatitis B infection is more frequent in Asia and underdeveloped nations. People who have both viruses infected are at a greater risk of getting liver cancer, cirrhosis, and chronic hepatitis.

Based on information from the GLOBOCAN 2020 web portal, which provides statistics on cancer around the world. They estimated that between 2020 and 2040, the incidence of liver cancer would rise by 55.0% and the number of fatalities would rise by 56.4%. As a result, primary liver cancer has always posed a serious risk to world health, both now and in the future. The leading causes of liver cancer DALYs and death are still the hepatitis B and C viruses,

Worldwide, the third leading disease that results in death is liver cancer, which is the sixth most common cancer overall. Over 700,000 cancer deaths occur each year as a result of it, making it a major factor in cancer mortality.

Regional differences in liver cancer incidence are significant. As per WHO, the rates are higher among American Indian or Alaska Native people in the US. The sixth most common cancer that leads to mortality in the US is liver cancer.

Compared to the US, Southeast Asia, and Sub-Saharan Africa have greatly higher rates of liver cancer. It is the most common type of cancer in a lot of these nations. For instance, chronic viral hepatitis is more common in East Asia, although Europe has the greatest rates of excessive alcohol consumption. Regional variations are also seen in the incidence and fatality rates of liver cancer.

Over 700,000 people die each year from liver cancer, which is an important cause of cancer mortality globally. Egypt was the country with the second-highest overall rate of liver cancer in 2020, after Mongolia. East Asia, Southeast Asia, and sub-Saharan Africa all have higher rates of liver cancer than Western nations.

Understanding this disease's causes, risk factors, and management techniques is more urgent than ever because it continues to claim lives and put a significant strain on healthcare systems around the world. As a result, there are wide-ranging and developing prospects for industry participants in the liver cancer market. Innovative diagnostics, targeted medicines, and treatment alternatives are becoming more and more in demand as a result of rising incidence rates and technological developments in medicine.

Disease Landscape Insights (DLI) healthcare consultancy firm plays a pivotal role in helping market players navigate the dynamic and competitive landscape of the liver cancer market, ultimately contributing to the development and delivery of more effective liver cancer diagnostics and treatments.

Diagnostic Analysis

"Liver Cancer Diagnosis and Screening Technologies"

Diagnosing liver cancer typically involves a combination of medical history assessment, physical examination, and various diagnostic tests. Liver cancer, also known as hepatocellular carcinoma (HCC), is challenging to diagnose in its early stages because symptoms do not manifest until the disease has progressed. More than 800,000 people are diagnosed with liver cancer every year worldwide.

Here are various diagnostic methods and tests used for the evaluation of liver cancer:

  1. Medical History and Physical Examination:

A healthcare provider takes a detailed medical history, asking about risk factors such as alcohol consumption, hepatitis infection, family history of liver cancer, and any symptoms the patient is experiencing. A physical examination reveals signs such as an enlarged liver or jaundice.

  1. Laboratory Test

Several blood tests help in the diagnosis and assessment of liver cancer, there are three major tests include:

  • Liver Function Tests: These tests measure the levels of liver enzymes, bilirubin, and other substances in the blood, which indicates liver damage or dysfunction.
  • Alpha-Fetoprotein (AFP) Test: Elevated AFP levels are associated with liver cancer, although this test is not specific to liver cancer and also be elevated in other liver conditions.
  • Des-Gamma-Carboxy Prothrombin (DCP) Test: DCP is another biomarker that is elevated in liver cancer and is used in conjunction with AFP.
  1. Imaging Studies:

Additionally, various imaging techniques are used by healthcare providers to visualize the liver and detect abnormalities. These include:

  • Ultrasound: Abdominal ultrasound helps identify liver tumors, although it may not always distinguish between benign and malignant lesions.
  • Computed Tomography (CT) Scan: CT scans provide detailed cross-sectional images of the liver, helping to determine the size, location, and extent of liver tumors.
  • Magnetic Resonance Imaging (MRI): MRI offers excellent soft tissue contrast and is used to further evaluate liver tumors, especially in cases where CT findings are inconclusive.
  • Angiography: Hepatic angiography involves injecting contrast dye into the blood vessels of the liver to visualize blood flow. It helps identify tumors and evaluate their blood supply.
  1. Liver Biopsy:

A liver biopsy involves taking a small sample of liver tissue for examination under a microscope. It definitively confirms the presence of liver cancer and provides information about its type and grade. Biopsies are obtained through various methods, including percutaneous (through the skin), laparoscopic, or surgical approaches.

  • Endoscopy: Endoscopic procedures such as Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) are used to evaluate the liver and bile ducts, particularly in cases where cancer has spread to these areas.
  • Positron Emission Tomography (PET) Scan: PET scans help to determine if cancer has spread to other parts of the body, such as the lymph nodes or distant organs.
  1. Genetic and Molecular Testing:

In some cases, genetic and molecular tests are performed to characterize the specific genetic mutations or alterations in the tumor. This information helps guide treatment decisions, particularly in the era of targeted therapies.

The choice of diagnostic tests and the order in which they are conducted depends on the patient's clinical presentation, risk factors, and initial findings. A multidisciplinary approach involving specialists in hepatology, oncology, radiology, and pathology is often necessary to accurately diagnose and stage liver cancer.

The demand for diagnostic tests for liver cancer is increasing and is quite competitive. Market participants use new technology to develop a variety of diagnostic kits. Additionally, the development of rapid, inexpensive diagnostic techniques is crucial for the diagnosis of liver cancer.

DiseaseLandscape Insights assists the industry players and delivers data on the current market and competitors and their products to better understand market dynamics. It also supports the development of various diagnostic kits and the use of new technologies to improve the current diagnostic process. Accordingly, stakeholders pick the direction of their business and adopt strategies for the market's expansion by using the data from DLI.

The following table lists the names of the market leaders who are redefining healthcare with their forefront diagnostic innovations:

                                                                          Diagnostic Market Players

Imaging Studies

Laboratory Test

Biopsy Equipment’s

Siemens Healthineers

Roche Diagnostics

Siemens Healthineers

General Electric (GE) Healthcare

Siemens Healthineers

Karl Storz

Philips Healthcare

Abbott Laboratories

Fujifilm Medical Systems

Toshiba (now Canon Medical Systems)

Beckman Coulter

Hitachi Medical Systems

Hitachi Healthcare

Ortho Clinical Diagnostics

GE Healthcare

SiCare Medical

Bio-Rad Laboratories

Philips Healthcare

Neusoft Medical Systems


Pentax Medical

Shimadzu Medical Systems

Sysmex Corporation


Carestream Health







                                                                          Diagnostic Market Product

Imaging Studies

Laboratory Test

Biopsy Equipment’s

Vantage Galan 3T, Vantage Titan 1.5T

Elecsys AFP Immunoassay

Biograph PET/CT Systems

Echelon Oval, Echelon Smart

ADVIA Centaur AFP Assay

Ingenuity TF PET/CT System



Discovery PET/CT 710

NeuViz 64, NeuViz 128

Alpha-Fetoprotein (AFP) Assay

Echelon Oval Superconducting 1.5T MRI

OnSight 3D Extremity System



Trillium Oval, Trillium II

HISCL-5000 Immunoassay System


Ingenia Ambition, Ingenia Elition

CL-2000i Chemiluminescence Immunoassay






"Innovations and Advancements in Liver Cancer Treatments"

Treatment Analysis

Treatment options for liver cancer depend on several factors, including the stage of the cancer, the patient's overall health, and the specific type of liver cancer. Here is an analysis of various treatment options for liver cancer,

  1. Surgery:

Resection and Hepatectomy:  Surgical removal of the tumor and a portion of healthy liver tissue. This is often an option for early-stage liver cancer. This involves removing a portion of the liver with the tumor. It's an option when the tumor is small and has not spread significantly

Liver Transplantation: In cases where the cancer cannot be removed entirely, a liver transplant is considered, especially for patients with cirrhosis and early-stage hepatocellular carcinoma (HCC).

  1. Ablation Therapy:

Ablation therapy for liver cancer is a minimally invasive procedure that offers a promising treatment option for patients with small liver tumors or those who are ineligible for surgery. This technique, which includes Radiofrequency Ablation (RFA), Microwave Ablation (MWA), and Cryoablation, involves the precise delivery of heat or cold energy to destroy cancerous tissue within the liver.

  • Radiofrequency Ablation (RFA): The use of high-energy radio waves to heat and destroy cancer cells. It is effective for small liver tumors.
  • Microwave Ablation: Similar to RFA but uses microwaves to heat and destroy cancer cells.
  • Ethanol Ablation: Injection of alcohol directly into the tumor to kill cancer cells.
  1. Embolization:

Trans arterial Chemoembolization is a procedure in which chemotherapy drugs are delivered directly to the liver tumor through its blood supply, followed by the embolization of blood vessels to cut off the tumor's blood supply. Another therapy is Radioembolization (Yttrium-90) in which radioactive microspheres are injected into the liver arteries to target and destroy cancer cells while sparing healthy tissue.

  1. Targeted Therapy:

Targeted therapies are designed to interfere with specific molecules or pathways that play a role in cancer growth. These drugs are effective for individuals with advanced liver cancer, particularly those with specific genetic mutations or biomarkers that make them suitable for targeted treatments. Certain drugs used to treat liver cancer are Sorafenib and Lenvatinib.

  • Sorafenib: A targeted therapy drug that inhibits the growth of new blood vessels in the tumor and blocks signals that promote cancer cell growth.
  • Lenvatinib: Another targeted therapy drug used to treat advanced hepatocellular carcinoma.
  1. Immunotherapy:

Immunotherapy plays a big role in treating liver cancer by stimulating the patient's immune system to recognize and attack cancer cells. Immune checkpoint inhibitors and other immunotherapeutic agents are being researched and used in clinical trials for advanced liver cancer cases.

Checkpoint Inhibitors drugs like nivolumab and pembrolizumab help the immune system recognize and attack liver cancer cells and CAR-T Cell Therapy is an experimental therapy that involves modifying a patient's T cells to target and destroy liver cancer cells.

  1. Chemotherapy:

Systemic chemotherapy is used in advanced cases or when other treatments are not effective, but it's generally less effective for liver cancer compared to other options.

Systemic chemotherapy involves the use of drugs that circulate throughout the body to target and kill cancer cells. While it's less effective for liver cancer than for some other cancers, it is used in cases where surgery or other treatments are not feasible. Targeted therapies and immunotherapy have also emerged as promising options within the chemotherapy realm.

  1. Radiation Therapy:

Radiation therapy, often referred to as radiotherapy, is a crucial treatment for liver cancer, particularly when surgery or other local treatments are not feasible. It involves the precise delivery of high-energy X-ray or proton beams to target and destroy cancer cells within the liver. Radiation therapy is administered externally (external beam radiation) or internally (brachytherapy), depending on the patient's specific condition. It is used both as a curative treatment to shrink tumors before surgery or as a palliative measure to relieve symptoms and slow the progression of advanced liver cancer.

External Beam Radiation and Internal Radiation Therapy (SIRT): are types of radiation therapy that work on High-energy X-rays that are targeted at the tumor to kill cancer cells and selective radioactive microspheres are injected into the liver arteries to deliver radiation directly to the tumor.

The choice of treatment depends on the patient's case and should be determined in consultation with a multidisciplinary team of healthcare professionals, including oncologists, surgeons, and radiologists. Early detection and a personalized treatment plan greatly improve the prognosis for liver cancer patients.

Emerging treatments

Emerging treatments for liver cancer are continuously being developed to improve patient outcomes and expand therapeutic options. Some of the promising emerging treatments for liver cancer include

  • Chimeric Antigen Receptor (CAR) T-cell Therapy: CAR-T cell therapy, which has been successful in treating certain blood cancers, is being investigated for liver cancer. This approach involves modifying a patient's T cells to target specific proteins on the surface of liver cancer cells, effectively harnessing the immune system to fight the disease.
  • Liquid Biopsies and Personalized Medicine Advances in genomic profiling and liquid biopsy techniques enable the identification of specific genetic mutations and alterations in liver cancer. This information guides the selection of targeted therapies and personalized treatment plans tailored to the patient's unique cancer profile.

These emerging treatments for liver cancer offer hope for improved outcomes and quality of life for patients.

DiseaseLandscape Insights supports the market participants to transform and expand in the treatment domain of liver cancer disease in order to improve patient retention, explore innovations in the treatment area, and achieve new business heights.

With extensive study of treatment choices, service contributions, product inventories, and market competitiveness, DLI enables market participants to stay one step ahead of the competition. We provide comprehensive assistance in planning, carrying out, and assessing clinical studies for the development of revolutionary new medications as a committed partner to the pharmaceutical industry.

The market for liver cancer is extremely competitive and demands a major player and assistance for a global presence.  To improve health outcomes, the market leaders in the table below are reshaping the environment and promoting innovation.

                                                                  Treatment Market Players

Ablation Therapy






Boston Scientific

Regeneron Pharmaceuticals




Merck & Co

Merit Medical


Eli Lilly

Varian Medical Systems




Bristol Myers Squibb




Incyte Corporation

Sirtex Medical





Bristol-Myers Squibb



Ablation Therapy



OsteoCool RF Ablation System

Nivolumab (Opdivo)


Habib EndoHPB Catheter



NanoKnife System



Sonablate HIFU



Emprint Microwave Ablation System



Axxent Electronic Brachytherapy System






SIR-Spheres Y-90



Echelon Flex Endopath Staplers




"Market Growth Factors and Drivers in Liver Cancer "

Market Trend Analysis

The liver cancer market has been experiencing significant shifts in recent years, driven by a combination of advancements in research and treatment modalities, as well as changing demographics and risk factors. Market trends in liver cancer are evolving rapidly, reflecting both challenges and opportunities in the field of oncology.

The global increase in liver cancer incidence is one obvious market trend. Multiple variables, including the rising prevalence of risk factors such as hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol addiction, are blamed for this rise. As a result, there is an expanding patient population that requires liver cancer detection and treatment, expanding the market for pharmacological and therapeutic interventions.

Furthermore, the liver cancer market is witnessing a transformation in the treatment landscape. Traditional treatment options, such as surgery and chemotherapy, are being supplemented and, in some cases, replaced by more targeted therapies. Immunotherapy and molecularly targeted agents are emerging as promising approaches, offering patients potentially more effective and less toxic treatment options. These therapies are designed to target specific genetic and molecular markers, providing personalized treatment strategies.

Additionally, another major development in the market for liver cancer is the development of new imaging and diagnostic methods. Early detection is essential for increasing survival rates, and non-invasive diagnostic techniques like liquid biopsies and cutting-edge imaging technologies are becoming more popular. These developments make it possible for medical professionals to identify liver cancer in its earliest stages, allowing for prompt treatment and better patient outcomes.

Additionally, combined medicines are becoming more prevalent in the market for treating liver cancer. To improve therapy effectiveness and circumvent resistance mechanisms, combinations of immunotherapies, targeted therapies, and conventional medicines are being investigated. This strategy tries to give patients more thorough and individualized treatment plans.

Furthermore, the emergence of artificial intelligence (AI) and machine learning is playing a significant role in the liver cancer market. These technologies are being applied to analyze medical imaging data, predict patient outcomes, and assist in treatment planning. AI-driven solutions have the potential to improve diagnostic accuracy and treatment decision-making, leading to better patient care.

Rising incidence rates, changing treatment approaches, improvements in diagnostics, and the incorporation of cutting-edge technology are driving the dynamic changes that are taking place in the liver cancer market. Together, these trends present stakeholders in the area with potential and difficulties, with a significant focus on enhancing patient outcomes via early detection and individualized treatment methods. In the upcoming years, it is anticipated that the liver cancer market will experience more innovations and developments as research advances.

"Key Players and Competitive Landscape in Liver Cancer Market "

Competitive Analysis

Significant competition exists in the liver cancer market as numerous pharmaceutical and medical technology companies work to provide cutting-edge diagnostic and therapeutic approaches. The increasing prevalence of liver cancer worldwide and the need for better diagnostic equipment and therapeutic options to enhance patient outcomes are driving factors in this market's competition. In the market for liver cancer diagnosis and treatment, several significant competitors are engaged in cutting-edge rivalry, and innovation is becoming increasingly important.

One of the notable players in the liver cancer market is Roche, which has been at the forefront of innovation. New diagnostic tests for liver cancer have been developed by Roche's diagnostic division, including liquid biopsy-based solutions that offer non-invasive techniques to find and monitor liver cancer. These advancements are meant to give doctors improved resources for monitoring, early detection, and individualized treatment selections.

Another prominent player is Bayer, which has been focusing on developing targeted therapies for liver cancer. Their research and development efforts have led to the approval of medications like sorafenib and regorafenib, which have significantly improved treatment options for liver cancer patients. Bayer continues to explore new therapeutic approaches and combinations to enhance treatment outcomes.

Similarly, the liver cancer treatment market has seen significant contributions from Bristol-Myers Squibb (BMS). Nivolumab, an immunotherapy medication from BMS, and ipilimumab have demonstrated excellent outcomes in clinical trials for advanced liver cancer. This immunotherapy strategy, which uses the body's immune system to combat cancer cells, marks a breakthrough in the treatment of liver cancer.  

In the domain of medical devices, Siemens Healthineers has been a key player. They have developed advanced imaging technologies, including high-resolution MRI and CT scanners, which aid in the early detection and precise staging of liver cancer. These innovations enable healthcare professionals to make more informed treatment decisions and improve patient outcomes.

Furthermore, startups and smaller companies have also entered the liver cancer market with innovative solutions. For instance, GRAIL, a healthcare company specializing in early cancer detection through blood-based tests, is exploring the potential to detect liver cancer at its earliest stages. Their research holds promise for improved survival rates and treatment outcomes.

The liver cancer market is witnessing continuous advancements in precision medicine, immunotherapy, and diagnostic technologies. These innovations are driven by a growing understanding of the molecular mechanisms underlying liver cancer and the need for more targeted and effective treatments. As competition in this market intensifies, patients expect to benefit from a broader range of treatment options, improved diagnostic accuracy, and ultimately, better outcomes in the fight against liver cancer. It's evident that the key market players and emerging innovators are working collaboratively to address the complex challenges posed by this devastating disease.

By providing in-depth knowledge about all current market participants, their innovations, strategies, and alliances, DiseaseLandscape Insights supports industry and companies. It additionally supports choosing the best market to expand rapidly.

Regulatory Framework Analysis

The regulatory framework for liver cancer, especially regarding drug approvals and diagnostic tools, has been undergoing significant developments in recent years. Several notable approvals have been granted to market players, reflecting advancements in the fight against this complex and often deadly disease

In the regulatory landscape, the emphasis has been on accelerating the approval process for treatments that demonstrate promise in addressing the complexities of liver cancer. Accelerated approvals and the expansion of treatment options for HCC patients reflect a growing recognition of the need for innovative therapies in this challenging disease area

Significant progress has been made in the development and regulatory assessment of liquid biopsies for liver cancer. These non-invasive tests analyze blood for circulating tumor DNA (ctDNA) and other biomarkers to detect and monitor liver cancer.

In 2020, the FDA granted accelerated approval to Pembrolizumab for the treatment of patients with hepatocellular carcinoma (HCC) who had been previously treated with sorafenib. This immune checkpoint inhibitor represents a significant advancement in the immunotherapy approach to liver cancer.

Nivolumab, another immune checkpoint inhibitor, received accelerated FDA approval in 2017 for HCC patients previously treated with sorafenib. Subsequent approvals in 2019 extended its use in first-line treatment for HCC.

These advancements underscore the commitment of regulatory bodies to fostering innovation and improving outcomes for individuals affected by liver cancer. As research and development continue, collaboration between regulatory agencies, healthcare providers, and the pharmaceutical industry remains essential in advancing the fight against liver cancer.

The DiseaseLandscape Insights takes into consideration the regulatory frameworks of various nations for liver cancer. The significant players in the market receive information from DLI regarding risk assessment laws, import/export laws, and surveillance. By choosing DLI services market players prevent and respond to liver cancer outbreaks for the safety and well-being of the impacted population.

Clinical Trial Assessments Analysis

The government's increasing emphasis on comparative effectiveness studies has brought focus on the value of clinical trials in evidence-based medicine and healthcare transition. Clinical data help achieve one of the key objectives of the healthcare revolution by enabling market participants to precisely compare medical therapy.

Phase 1

Phase 2

Phase 3

Phase 4

A Phase I, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerance, and Pharmacokinetics of OH2 Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

Modulation of Sorafenib-Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

A Phase II/III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1 Inhibitor Via Hepatic Arterial Infusion Versus Vein for Immunotherapy of Advanced Liver Cancer

Improving Response to Immunotherapy in Patients with Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection with Direct-Acting Antiviral Therapy

rRp450-Phase I Trial in Liver Metastases and Primary Liver Tumors

Phase II Basket Trial of Domvanalimab (AB154) and Zimberelimab (AB122) in Advanced Hepatobiliary Cancers

Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection

Prospective Randomized Double-Blind Study of Pain Control with Hepatic Hilum Nerve Block Versus Sham Procedure for Hepatic Chemoembolization or Radiofrequency Ablation

The Clinical Value of 3D Self-healing Elastic Liver Model for Surgical Training and Preoperative Planning: A Preliminary Study

Clinical Recruitment of Patients with First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab, JS001) Detected on the NGS Platform Combined with Anlotinib

Clinical Impact of a Volumetric Image Method for Confirming Tumor Coverage with Ablation on Patients with Malignant Liver Lesions (COVER-ALL)

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)

Phase II Study of TSR-022 (Cobolimab) in Combination With TSR-042 (Dostarlimab) for the Treatment of Advanced Hepatocellular Carcinoma

Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients with Primary Liver Cancer: A Randomized Controlled Trial

Abbreviated MRI (AMRI) vs. Ultrasound for HCC Surveillance in Cirrhosis

A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumors

Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined with leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)

Applicability of Patient Derived Orthotopic Xenograft (PDOX) in Patients with Primary Liver Cancer: A Randomized Controlled Trial

Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia with Sevoflurane

First in Human Dose Escalation Study of AU409 in Patients with Advanced Primary Liver Cancers or Advanced Solid Tumor with Liver Predominant Metastatic Disease

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)

Prospective, Randomized Controlled, Single-center, Phase III Clinical Study of TACE Combined with Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

Pre- vs Postoperative Thromboprophylaxis for Liver Resection - a Prospective, Multicenter, Randomized Controlled Trial



For healthcare organizations looking to effectively manage liver cancer, DiseaseLandscape Insights (DLI), a healthcare consulting firm, is ready to offer a wide range of strategic services to all our stakeholders. Services with a wide range of expertise include conducting market research and analysis to identify trends and opportunities.

Additionally, DLI also ensures regulatory compliance on utilizing clinical expertise for evidence-based approaches, developing creative product development strategies, facilitating collaboration with important stakeholders, and more.

DLI services are equipped to navigate clients on the complex landscape of cancer management and help them make informed choices that improve patient outcomes by providing personalized recommendations.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape